	US 11,866,688 B2
	Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
Cecile Chartier-Courtaud, Palo Alto, CA (US); and Krit Ritthipichai, Tampa, FL (US)
Assigned to Iovance Biotherapeutics, Inc., San Carlos, CA (US)
Filed by Iovance Biotherapeutics, Inc., San Carlos, CA (US)
Filed on Jul. 1, 2022, as Appl. No. 17/810,542.
Application 17/810,542 is a continuation of application No. 17/387,357, filed on Jul. 28, 2021, granted, now 11,384,337.
Application 17/387,357 is a continuation of application No. 17/050,552, previously published as PCT/US2019/029286, filed on Apr. 26, 2019.
Claims priority of provisional application 62/680,821, filed on Jun. 5, 2018.
Claims priority of provisional application 62/663,885, filed on Apr. 27, 2018.
Prior Publication US 2022/0396769 A1, Dec. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0783 (2010.01); A01N 1/02 (2006.01); A61K 35/17 (2015.01); C12N 9/22 (2006.01); C12N 15/113 (2010.01)

CPC C12N 5/0638 (2013.01) [A01N 1/0221 (2013.01); A01N 1/0226 (2013.01); A61K 35/17 (2013.01); C12N 9/22 (2013.01); C12N 15/113 (2013.01); C12N 2310/20 (2017.05); C12N 2501/2302 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/2321 (2013.01); C12N 2501/515 (2013.01)]

9 Claims

1. A gene-edited tumor infiltrating lymphocyte (TIL) composition comprising:

i) a therapeutic population of gene-edited TILs, wherein at least a portion of said therapeutic population of gene-edited TILs comprises silenced or reduced expression of two immune checkpoint genes, wherein said two immune checkpoint genes comprise PD-1 and TIGIT, and

ii) a cryopreservant;

wherein the therapeutic population of gene-edited TILs exhibits increased IFN-γ secretion by at least five-fold in vitro as compared to a non-expanded population of TILs.